Solventum Q3 sales flat at $2.082B; adjusted EPS $1.64, raises FY guidance

Solventum Corp

2024-Q3 EPS reported $2.58 revenue$6,179,000,000

GAAP EPS $0.70, adjusted EPS $1.64; operating income $275M GAAP, $475M adjusted.
Reported sales +0.4% YoY; organic sales +0.3%; MedSurg and HIS led growth.
Free cash flow $76M; cash from operations $169M.
Full-year organic sales growth, adjusted EPS, and free cash flow guidance raised.
CEO cites consecutive outperformance; supply agreement mark-up impacted margins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.